UNSPSC 51372107: Hydromorphone

This classification denotes an opiate with the molecular formula C17H19NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Q812464R06, chemically known as morphinone, dihydro-, hydrochloride but generally known as hydromorphone, which bears US NIH Compound Identifier 3648. European Medicines Agency schedules Hydromorphone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08070MIG. The term HYDROMORPHONE is an International Non-Proprietary Name.

UNSPSC 51372107 Hydromorphone, a Commodity code, identifies opioid pharmaceuticals and related controlled substances that state and local governments procure primarily through pharmacy benefit programs, cooperative purchasing alliances, and community health initiatives. Recent solicitations show state and local buyers acquiring hydromorphone and related products—including naloxone and multi-source generic pharmaceuticals—for distribution through authorized wholesalers to health facilities, employee benefit programs, and community health departments. Issuing bodies include state health and human services commissions, county health departments, and multistate cooperative purchasing alliances serving participating state and local jurisdictions. The work involves establishing supply contracts with manufacturers and wholesalers, negotiating pricing structures, ensuring compliance with FDA manufacturing practices and Drug Supply Chain Security Act requirements, and managing quarterly or ongoing deliveries to designated facilities.

Activity under the code spans Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS in June 2026, due July 26, 2023, to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to its Community Health Building. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 seeking vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 in January 2026 with a due date of March 26, 2026, to establish multiple-award contracts for generic pharmaceuticals and over-the-counter products distributed through three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co.) to participating state and local facilities in Minnesota and Oregon. The MMCAP procurement emphasizes price competitiveness (75 percent evaluation weight), cGMP and DSCSA compliance, and maintenance of relationships with authorized wholesalers.